HOTH News and Press, Hoth Therapeutics Inc. From 03/10/22

The shares of development-stage biopharma company, Hoth Therapeutics (HOTH +44.7%) have gained sharply on Thursday after the U.S. Food and Drug Administration (FDA) granted it the Orphan Drug Designation for a potential therapy targeted at mastocytosis. According to the FDA database, the desi...

Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients PR Newswire NEW YORK , Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharma...

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the trea...

Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ for the treatment of Alzheimer's disease ...

2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the hottest stocks in the market today is Hoth Therapeutics (NASDAQ: HOTH ). Indeed, HOTH stock has more than doubled on incredible volume today as investors price in a very significant catalyst. Source: luc...

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease Significant decrease in Aβ seen in an Alzheimer's disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ has the potential to modi...

Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis PR Newswire NEW YORK , Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutica...

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics Hoth to receive shares in Zylö and potential future sales royalties PR Newswire NEW YORK , Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage b...

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way PR Newswire NEW YORK , Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused ...